NCT06958484View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

December 31, 2027

Conditions
HCC - Hepatocellular CarcinomaAdjuvant Treatment
Interventions
DRUG

Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab

The patients with high-risk recurrence will be treated with Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment .

All Listed Sponsors
lead

The Affiliated Hospital of Xuzhou Medical University

OTHER